NASDAQ · ZYME
Healthcare · Biotechnology
$25.65
Up+$0.88 (+3.43%)
Updated Oct 8, 2026, 12:32 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ZYME
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ZYME closed at $25.65 after 20 trading sessions, down 5.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $26.42 | $26.79 | $25.51 | $25.65 | 1.47M |
| Oct 5, 2026 | $25.37 | $26.505 | $25.28 | $26.21 | 1.04M |
| Oct 2, 2026 | $26.18 | $26.19 | $25.04 | $25.15 | 844.45K |
| Oct 1, 2026 | $26.44 | $26.56 | $25.88 | $25.96 | 808.7K |
| Sep 30, 2026 | $27.25 | $27.73 | $26.47 | $26.49 | 1.59M |
| Sep 29, 2026 | $27.12 | $28.26 | $26.76 | $27.20 | 999.91K |
| Sep 28, 2026 | $25.94 | $27.54 | $25.66 | $27.12 | 1.38M |
| Sep 25, 2026 | $26.86 | $26.88 | $26.225 | $26.52 | 1.09M |
| Sep 24, 2026 | $27.13 | $27.495 | $26.14 | $26.81 | 752.93K |
| Sep 23, 2026 | $27.55 | $27.89 | $26.525 | $27.50 | 647.75K |
| Sep 22, 2026 | $26.72 | $27.70 | $26.55 | $27.565 | 446.03K |
| Sep 21, 2026 | $26.84 | $27.1699 | $26.19 | $26.81 | 582.62K |
| Sep 18, 2026 | $27.45 | $27.55 | $26.38 | $26.57 | 1.1M |
| Sep 17, 2026 | $27.15 | $27.855 | $26.715 | $27.48 | 1.33M |
| Sep 16, 2026 | $26.17 | $26.55 | $25.91 | $26.24 | 686.99K |
| Sep 15, 2026 | $26.61 | $26.785 | $25.81 | $26.05 | 552.16K |
| Sep 14, 2026 | $26.80 | $27.135 | $26.2301 | $26.85 | 711.03K |
| Sep 11, 2026 | $26.62 | $26.99 | $26.03 | $26.24 | 1.03M |
| Sep 10, 2026 | $26.81 | $27.04 | $26.39 | $26.435 | 585.29K |
| Sep 9, 2026 | $27.81 | $28.09 | $27.08 | $27.15 | 396.03K |
The latest Smart Investors Daily articles mentioning ZYME.
Company
Market Activity
Research & News
ZYME research
Company profile and research snapshot.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Citigroup | Buy | — |
| Sep 17, 2026 | Wolfe Research | Outperform | — |
| Sep 3, 2026 | JP Morgan | Overweight | — |
| Aug 26, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 26, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Zymeworks (NASDAQ:ZYME) said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a commercial organization to its business. Management said the transaction represent
Benzinga · Sep 29, 2026
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $38 to $39.
SeekingAlpha · Sep 28, 2026
Zymeworks Inc. (ZYME) M&A Call September 28, 2026 8:30 AM EDTCompany ParticipantsShrinal Inamdar - Vice President of Investor RelationsScott Platshon -...
Benzinga · Sep 28, 2026
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZYME.
